DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-Reference-Cited by-同舟云学术

DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)

Published:2019-07-08 Issue:10 Volume:58 Page:1502-1505
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Evensen Jan Folkvard¹,Sand Hansen Hanne²,Overgaard Marie³,Johansen Jørgen⁴,Andersen Lisbeth Juhler⁵,Overgaard Jens⁶

Affiliation:

1. Norwegian Radium Hospital, Oslo, Norway;

2. Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;

3. Department of Oncology, Aarhus University Hospital, Aarhus N, Denmark;

4. Department of Oncology, Odense University Hospital, Odense C, Denmark;

5. Department of Oncology, Aalborg University Hospital, Aalborg, Denmark;

6. Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

Funder

Danish Cancer Society

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1629012

Reference20 articles.

1. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

2. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial

3. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

4. Study of the Population Pharmacokinetic Characteristics of Nimorazole in Head and Neck Cancer Patients Treated in the DAHANCA-5 Trial

5. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses;Radiotherapy and Oncology;2024-01

2. A Comparative Prospective Study Between Conventional Chemo-Radiotherapy and Pure Accelerated Radiotherapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Head and Neck Cancer;Cureus;2023-07-20

3. Role of Organ Preservation in Locally Advanced Hypopharyngeal Carcinoma;Pharynx - Diagnosis and Treatment;2021-09-08

4. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines;Radiotherapy and Oncology;2020-10

5. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity;Radiotherapy and Oncology;2020-07